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The application of serum biomarker to ovarian tumors for early stage detection and clinical diagnosis is a
rapidly expanding research area. The problem with conventional markers is that they are often released
too late or at too low a level to be detected in time to trigger effective treatment. Ultrasound has been
used to inﬂuence bio-effects in living cells, but there is only one reported case of the use of ultrasound
to enhance the release of a biomarker (Carcinoembryonic antigen CEA). In this study we report the use
of ultrasound to enhance the release of a combination of ovarian cancer biomarkers (CA125 and CA19-
9) to help in the diagnosis of ovarian cancer at an early stage. The results indicated that after 5 min son-
ication at a frequency of 1 MHz and intensity of 0.3 W cm2, the CA125 and CA19-9 levels were increased
by 2.02 and 4.21-fold respectively. These ﬁndings suggest that ultrasonic treatment can be used to
enhance the release of serum biomarkers from ovarian tumors.
 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-SA license.1. Introduction
Ovarian cancer is one of the leading causes of cancer deaths
among women but if the disease is treated at an early stage there
is an excellent prognosis for survival following treatment. However
some 70% of patients are diagnosed at an advanced stage and in
this case there is a poor survival rate of only 10–30% therefore it
is important to detect ovarian cancer at early stage [1,2]. Current
diagnosis methods for ovarian cancer are the CA-125 blood test
and transvaginal ultrasound [3]. But neither of these tests are suf-
ﬁciently sensitive or speciﬁc [4]. Recently, biomarkers such as
CA125 and CA19-9 have been used to help in the early screening
and diagnosis of ovarian cancer i.e. at a stage when it is the most
treatable and before it has had a chance to grow and spread
[5–8]. CA125 is the most widely used tumor marker in ovarian
cancer but its sensitivity and speciﬁcity are not ideal because the
levels of this marker are raised to approximately 80% of all epithe-
lial ovarian cancers (EOC) and in only 50% of stage I EOC. The
sensitivity and speciﬁcity rates of another biomarker CA19-9 are
both lower than those of CA125. From this it can be argued that
the results from individual existing markers are not speciﬁcenough because they can be affected by other malignancies, benign
conditions such as diverticulitis, liver cirrhosis and also by physio-
logical conditions including menstruation and pregnancy. In addi-
tion the concentration of a biomarker signal in the blood is often
very low and so is difﬁcult to detect. In order to be used in screen-
ing for early stage cancer the tumor marker must be sufﬁciently
detectable to provide a positive result. Research [9–16] suggests
that the use of a combination of biomarkers improves sensitivity
for the detection of ovarian cancer.
Ultrasound has been shown to be effective in a range of cancer
therapies including the direct killing of cancer cells, enhanced drug
delivery and for improving membrane permeability for the uptake
of drugs. In 2009, researchers [17] reported the use of ultrasound
to increase the release of biomarker Carcinoembryonic antigen
(CEA). In this study, ultrasound at 1 MHz with an intensity of
0.3 W cm2 was applied in cell culture experiments using the
human colon cancer cell line LS174T. The biomarker CEA concen-
tration was measured before and after exposure of the tumor cells
to ultrasound. After 30 min treatment there was a 4-fold increase
in the CEA levels when compared with untreated control samples.
Mouse tumor xenograft models were also tested using 1 MHz
ultrasound at an intensity of 2 W cm2 applied directly to the site
of the tumor for 6 min. The CEA level was increased by more than
10-fold, which may have been due to the somewhat higher inten-
sity used. The ultrasonic transducer applied in this work was a
commercial device (Sonitron 2000, Belgium), which can provide a
well collimated beam penetrating deep into the tissue. This work
indicated the possibilities that the concentration of tumor
452 D. Peng et al. / Ultrasonics 54 (2014) 451–454biomarkers in blood could be increased leading to a more sensitive
and speciﬁc diagnosis. As an extension of this it would be of inter-
est to determine whether ultrasonic treatment can enhance the re-
lease of two other ovarian tumor biomarkers CA125 and CA19-9 to
a concentration enabling early stage screening and a consequent
improvement in patient survival rate. One of the bio-effects of
ultrasound is to induce a temporary increase in the permeability
of the cell membrane. 1 MHz, continuous-wave ultrasound (8
W cm2) for 30 s treatment has been suggested to induce transient
pores in the cell membranes of some surviving cells [18]. This was
the driving force for our work which was to use this effect to pro-
vide a safe but effective ultrasonic treatment for the enhanced re-
lease of ovarian tumor biomarkers without causing permanent
damage to the human cells involved.
2. Materials and methods
2.1. Cells
Human ovarian carcinoma cell lines, SKOV3 were cultured in
McCOY’s 5A medium (12400024, Gibco, Life Technologies, USA)
supplemented with 10% fetal calf serum (SV30087.02, Hyclone
Laboratories Inc., USA) at 37 C and under 5% CO2 concentration.
Cells grew in incubator (SERIES 8000 WJ, Thermo Scientiﬁc, USA).
2.2. Ultrasonic equipment
The parameter settings of the HM-1 ultrasonic equipment
(Jiangsu Hanmei Science and Technology Co., Ltd., Taizhou, China)
were: frequency of 1 MHz, intensity of 0.3 W cm2 and 50% duty
cycle. The diameter of the ultrasonic probe was 21 mm. An ultra-
sound power meter (Model UPM-DF-1E, Ohmic Co., Ltd., USA)
was used for intensity measurement and an oscilloscope (model
TDS1000B, Tektronix Co., Ltd., USA) for the measurement of
frequency.
2.3. Ultrasonic treatment of cells
Cells were seeded at 5  106 in culture ﬂasks (Gibco, USA), and
grown overnight in complete media forming a 100% conﬂuent
monolayer of cells. On the following day, the media was removed
and the cells were rinsed three times with 2–3 mL fresh media.
5 mL cells were then added into culture ﬂasks immediately before
sonication. Ultrasonic treatment was applied from the bottom of
the ﬂask for 5 min. To achieve good sonication, ultrasound cou-
pling gel (Shengyou, Taizhou, China) was used between the bottom
of the ﬂasks and the ultrasonic probe, with the probe placed ﬂush
against the bottom of the ﬂasks (Fig. 1). Control samples were run
in parallel without sonication. Immediately after treatment 0.5 mL
samples of suspension were removed for analysis.Fig. 1. Schematic diagram of experimental set-up.2.4. CA125/CA19-9 quantiﬁcation
CA125 and CA19-9 concentration in media were determined
using a Roche automatic electrochemiluminescence immunoassay
analyzer (COBAS6000, Switzerland). The sensitivity of this method
was 0.6 U/mL.2.5. Cell death detection
Cell death was determined immediately after sonication. The
media was removed, the cells were harvested and cell death was
determined by adding 10% Trypan blue to the cell suspension. Only
dead cells with disrupted cell membranes are stained by the dye.
The percentage of dead cells was counted using an inverted micro-
scope (1X51, OLYMPUS, Japan) within 3 min after staining.2.6. Statistical analysis
Statistical analyses were done with SPSS17.0. All data are pre-
sented as the mean ± standard deviation (SD). Analysis of variance
(Univariate ANOVA) and t test were adopted. A signiﬁcance level of
0.05 was used.3. Results and discussion
3.1. Time release of CA125 from ovarian cancer cells in culture treated
with ultrasound
To study the time release of biomarkers, cells were sonicated
using the ultrasonic probe system described above. A signiﬁcant
increase of CA125 was observed from a treatment time of 5 min
and the biomarker concentration (P < 0.01) continued to increase
slowly over the remaining 30 min sonication. The average concen-
tration of CA125 after sonication was 6.26 U/mL, which was a 3-
fold increase in CA125 levels compared with control samples
(2.15 U/mL). The release of CA125 was also seen to increase slightly
(P > 0.05) without sonication but this was signiﬁcantly lower com-
pared with sonicated samples (Fig. 2). Similar reports of ultrasonic
effects on CEA were published by D’Souza et al. [17]. In our study
we found that the major increase occurred after 5 min treatment
but after this the continued increase of CA125 concentration was
slow (P > 0.05). Thus, we decided to set the sonication time in all
further experiments for 5 min.Fig. 2. Time release of CA125 from ovarian cancer cells in culture in the presence
and absence of ultrasound.
Fig. 3. Comparisons on time release of CA125 and CA19-9 in the presence and
absence of ultrasound.
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sonication
CA125 and CA19-9 levels observed after sonication were higher
than these without sonication (P < 0.01 in both cases). The initial
concentration of CA125 and CA19-9 were 2.19 ± 0.25 U/mL and
0.61 ± 0.01 U/mL, respectively. After sonication, the CA125 concen-
tration was 4.41 ± 0.09 U/mL and CA19-9 concentration was
2.38 ± 0.10 U/mL (Fig. 2). The results indicated that ultrasonic
treatment (1 MHz frequency, 0.3 W cm2 intensity and 50% duty
cycle) over a period of 5 min increased the concentration of both
of these biomarkers, conﬁrming that ultrasound can amplify tumor
biomarker release (see Fig. 3).
Ovarian cancer is the most frequent cause of death from gyne-
cological cancer and the fourth most common cancer-related killerFig. 4. Flow chart of exfor female patients. It is not easy to diagnose at early stage
although the cure/survival rate would be much higher if treatment
could be applied at this stage. The use of tumor biomarkers can im-
prove the accuracy of diagnosis and management of patients with
ovarian cancer. Unfortunately at an early stage the biomarker lev-
els are usually too low to be detected. The most widely used and
extensively researched tumor marker in ovarian cancer is CA125
but it cannot be used alone for cancer detection because only
50–60% of patients with stage I epithelial ovarian cancer will have
levels high enough to register positive. CA19-9 is another tumor
antigen. Although it is not used as widely as CA125 in ovarian can-
cer CA19-9 has been studied in the gynecological ﬁeld since the
1980s and shown to have prognostic signiﬁcance for tumor cells.
Compared with CA125 alone (64%), a combination of CA19-9 and
CA125 presents an increase in positivity rate to 100% [13]. Thus
the combined use of CA125 and CA19-9 offers the possibility of
improvements in sensitivity of ovarian cancer detection without
signiﬁcant loss in speciﬁcity. Our results also suggest the possibil-
ity that ultrasonic treatment could also increase the levels of other
markers e.g. HE4, CA72-4, SF and AFP.
The ultrasonic technique has been shown to produce pores in
the cell membrane without immediate killing effects and so can
cause a temporary increase in permeability [19]. Direct observa-
tion of the effects of sonication at 1.075 MHz (intensity not re-
ported) for 0.2 s on Xenopuslaevis oocytes revealed that 110 nm
pores were generated in the membrane [20]. These transient pores
in cell membranes provided channels through which macromole-
cules could pass. Based on this observation we deduce that this
type of effect can also enhance the movement of biomarkers out
of the cell. Although the mechanism of the formation of transient
pores in biological membranes induced by ultrasonic cavitation is
not fully understood, it is believed that they are associated with
the generation of shockwaves and microjects produced on bubbleperimental design.
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In addition, when an ultrasonic pressure wave is reﬂected and
meets the further transmitted waves, it will result in the formation
of an ultrasound standing wave ﬁeld. Standing waves can help in
achieving high sonoporation efﬁciency, but it is difﬁcult to induce
the standing wave in vivo for a clinical application. Thus, the for-
mation of a standing wave should be minimized for further work
either by the movement of the probe or the use of pulsed waves
[21,22].
Future investigations of these ultrasonic effects on biomarker
release from human cell lines will involve the use of a wider range
of parameter settings such as frequency, intensity, sonication time
and duty cycle.
3.3. Cell death after sonication
During 5 min sonication the percentage of cell death observed
was 2.12% (P < 0.01) compared with only 0.54% (P < 0.01) in the
control. An increase in the intensity of ultrasound would certainly
increase the rate of cell death but as a consequence of this there
might be some safety concerns for the patient. For this reason it
is important to maintain the ultrasonic parameters at levels sufﬁ-
cient to achieve ampliﬁcation of biomarker release but to minimize
cell death.
The American Federal Drugs Administration (FDA) has raised
the limit of permitted spatial peak temporal average intensity for
commercially available ultrasound devices from 0.094 W cm2 to
0.72 W cm2 with two safety-related indices, the thermal index
(TI < 6.0) and the mechanical index (MI < 1.9) [23]. The ultrasonic
intensity applied in our experiments was 0.3 W cm2 with TIS
(MI) of 5 (1.43), which was within the current safety requirement.
This study is at very early stage and the main achievement has
been to demonstrate that insonation can improve the ovarian tu-
mor biomarker level in blood.
Further investigations in this work are outlined in the ﬂow chart
(Fig. 4). At the cell culture stage the concentration of ovarian can-
cer biomarkers will be tested under deﬁned ultrasound parameters
(frequency, power, duty cycle, time). For the second stage, living
subjects will be treated using insonation at appropriate ultrasonic
parameter settings identiﬁed from the ﬁrst stage. Living subjects
will be observed before and after treatment to determine the
mechanism of action of the insonation. The biological effects of
ultrasound on the cell membrane will be studied. We will also
use animal studies in lead optimization to avoid unwanted cell
death. Treatment’s safety will be tested by cell survival rates. If
data from animal models can predict that the treatment is likely
to be safe and efﬁcacious for tumor biomarker release the study
will be carried onto clinical trials.
4. Conclusion
The experiments revealed that using a frequency of 1 MHz at an
intensity of 0.3 W cm2 over 5 min, CA125 and CA19-9 levels in-
creased by 2.02 and 4.21-fold respectively compared with control
experiments in the absence of ultrasound. There have been no pre-
vious reports about the use of ultrasound in connection with
CA125 and CA19-9 expression and transfer process. The mecha-
nism for enhanced release is not yet clear but the hypothesis is that
ultrasonic treatment increases cell membrane permeability [21].
Biomarkers produced in or on the cell surface are then released
into the blood.
The results strongly suggest that early stage diagnosis of ovar-
ian cancer may be possible using a combination of biomarkers in
combination with sonication.Acknowledgements
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